UTHR News & Analysis
2 articles
Market Mood
United Therapeutics (UTHR) Ranks 1st in Renaissance Technologies 2026 List
United Therapeutics Corporation (UTHR) is ranked 1st on Renaissance Technologies' list of top stocks for 2026. The fund disclosed its initial stake of 261,000 shares in UTHR in Q4 2010. As of Q1 2026, Renaissance owns nearly 1.8 million shares, a decrease of over 6% from Q4 2025. The company is preparing major NDA submissions to the FDA for Tyvaso, which aims to be the first inhaled anti-fibrotic treatment for Idiopathic Pulmonary Fibrosis, following positive data from its TETON studies.
Read More
United Therapeutics Corporation Form 144 Filed on May 7
United Therapeutics Corporation (UTHR) has submitted Form 144 on May 7, indicating the intent to sell a specified amount of securities. Form 144 is typically filed by affiliates of a company prior to selling restricted or control securities. The filing details may influence market perception of UTHR, particularly among investors tracking insider sales or ownership changes. Specific quantities or transaction values were not disclosed in the filing.
Read More